Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Judy Wen is active.

Publication


Featured researches published by Judy Wen.


Journal of Pediatric Surgery | 2000

Overexpression of Fas-ligand by neuroblastoma: A novel mechanism of tumor-cell killing

Shigeru Takamizawa; Shinya Okamoto; Judy Wen; Warren P. Bishop; Ken Kimura; Anthony D. Sandler

BACKGROUND/PURPOSE Binding of Fas ligand (Fas-L) to the membrane-bound Fas receptor incites a series of intracellular events that results in programmed cell death or apoptosis. Although this apoptotic phenomenon plays a key role in down-regulating cytotoxic T cells, the authors have shown previously that pancreatic beta cells (bTC) overexpressing Fas-L paradoxically undergo accelerated rejection that is dependent on a Fas/Fas-L interaction. This study evaluates whether a neuroblastoma (NB) cell line manipulated to overexpress Fas-L undergoes similar destruction and whether tumor-specific protective immunity can be produced. METHODS The authors transfected NB cells (SK-N-MC) with either mFas-L cloned into a pcDNA3.1/Zeo plasmid vector (NB/Fas-L) or with the vector alone (NB/control). Successful transfection of Fas-L was characterized by reverse transcription polymerase chain reaction (RT-PCR) and the ability of transfectants to induce apoptosis of Fas-sensitive T cells (Jurkat). Expression of Fas and Fas-L in untransfected NB clones was characterized by immunohistochemistry and RNase protection assay (RPA). Apoptosis was measured by FACScan analysis using an Annexin V assay. A total of 3x10(6) NB/control and NB/Fas-L cells were implanted subcutaneously into the hind leg of Balb/C SCID mice. Tumor-specific protective immunity was also tested in this model by inoculating mice with NB/Fas-L before implanting NB/control cells. RESULTS Zeocin resistance and RT-PCR confirmed successful transfection of Fas-L into NB cells. Fas Ligand transfectants induced apoptosis in 17.6%+/-2.9% of Fas-sensitive T cells, whereas controls induced apoptosis in only 2.8%+/-1.2% (P = .01, n = 3). Although Fas appears to be constitutively expressed by NB in low amounts, introduction of Fas-L into NB cells did not induce suicide or affect tumor cell growth in vitro. In vivo, NB cells expressing Fas-L failed to grow in SCID mice (n = 3), whereas controls grew rapidly in all animals until death (n = 3). NB/control cells implanted into the opposite leg of mice that rejected initial NB/Fas-L transfectants also grew rapidly (n = 3) implying no protective immunity. CONCLUSIONS Overexpression of Fas-L in NB clones targets such cells for rapid destruction even in immune compromised hosts, suggesting potential utility of Fas-L in combating NB. In this SCID mouse model, the observed effect is probably neutrophil mediated and does not provide tumor-specific protective immunity.


Journal of The American College of Surgeons | 2000

A novel murine neuroblastoma vaccine strategy

David Scott; Shigeru Takamizawa; Judy Wen; Arthur M. Krieg; Shinya Okamoto; Warren P. Bishop; Anthony D. Sandler

infancy, however, some are known to undergo spontaneous regression; the cellular mechanisms regulating growth and tumor regression are not known. GRP, a gut/neuropeptide, can alter the growth of cancers which possess GRP receptors (GRPR); the regulation of GRPR expression is largely undefined. The purpose of our study was twofold: 1) to determine the expression and cellular regulation of GRPR in the human neuroblastoma cell line IMR-32, and 2) to assess whether GRP affects IMR-32 cell growth.


Journal of Pediatric Surgery | 2001

The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma

Takeo Azuhata; David Scott; Shigeru Takamizawa; Judy Wen; Andrew Davidoff; Masahiro Fukuzawa; Anthony D. Sandler


Journal of Pediatric Surgery | 2001

The survivin: Fas ratio in pediatric renal tumors☆

Shigeru Takamizawa; David Scott; Judy Wen; Paul Grundy; Warren P. Bishop; Ken Kimura; Anthony D. Sandler


Journal of Pediatric Surgery | 2000

Differential Apoptosis Gene Expression in Pediatric Tumors of the Kidney

Shigeru Takamizawa; Shinya Okamoto; Warren P. Bishop; Judy Wen; Ken Kimura; Anthony D. Sandler


Journal of Surgical Research | 1999

Overexpression of Fas Ligand Does Not Confer Immune Privilege to a Pancreatic β Tumor Cell Line (βTC-3)

Shinya Okamoto; Shigeru Takamizawa; Warren P. Bishop; Judy Wen; Ken Kimura; Anthony D. Sandler


Journal of The American College of Surgeons | 2000

Survivin: expression and function in neuroblastoma

Takeo Azahata; David Scott; Shigeru Takamizawa; Judy Wen; Andrew M. Davidoff; Ken Kimura; Anthony D. Sandler


日本小児外科学会雑誌 | 2000

C64 神経芽細胞腫における Fas-L の発現 : 腫瘍消退のメカニズムー新しい知見

澤滋 高見; Anthony D. Sandler; 健 木村; 晋弥 岡本; Judy Wen; Warren P. Bishop


日本小児外科学会雑誌 | 2000

E35 肝芽腫における Fas ライガンド発現の免疫応答回避、自己細胞死における役割

澤滋 高見; 晋弥 岡本; Judy Wen; Warren P. Bishop; 健 木村; Anthony D. Sandler


Journal of the Japanese Society of Pediatric Surgeons | 2000

C60 肝芽種における化学療法、アポプトーシス受容体刺激併用による腫瘍治療効果

澤滋 高見; Joshua Rosebrook; Anthony D. Sandler; 健 木村; 晋弥 岡本; Judy Wen

Collaboration


Dive into the Judy Wen's collaboration.

Top Co-Authors

Avatar

Anthony D. Sandler

Children's National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Warren P. Bishop

University of Iowa Hospitals and Clinics

View shared research outputs
Top Co-Authors

Avatar

Shigeru Takamizawa

University of Iowa Hospitals and Clinics

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew M. Davidoff

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul Grundy

University of Iowa Hospitals and Clinics

View shared research outputs
Researchain Logo
Decentralizing Knowledge